Evaluating the effectiveness and risks of oral anticoagulant treatments in multimorbid frail older subjects with atrial fibrillation using the multidimensional prognostic index: the EURopean study of older subjects with atrial fibrillation—EUROSAF
- 40 Downloads
Previous studies suggested that a different risk of mortality may influence the oral anticoagulant prescription in older patients with atrial fibrillation (AF). Recently, the Multidimensional Prognostic Index (MPI) demonstrated a high grade of accuracy, calibration and feasibility to predict mortality in hospitalized and community-dwelling older people. Prognostic information, as calculated by the MPI, however, is not included in the decision algorithm of treatments in older patients with AF
The aim of this international multicenter prospective observational study was to evaluate whether a different prognostic profile, as determined by the MPI, is associated with different treatments for AF (no treatment vs oral anticoagulants) and differences in the main outcomes, i.e., mortality, major thromboembolic events and side effects.
Materials and methods
Older hospitalized patients (age ≥ 65 years) with non-valvular AF will be consecutively enrolled in an European, cross-national, prospective, observational study. At baseline, functional and clinical information will be collected to calculate the MPI, CHA2DS2-VASc score, HAS-BLED score, pharmacological treatments (and the compliance during follow-up) and main and secondary diagnoses. During the 12-month follow-up period, information on survival, major thromboembolic events and major bleeding will be collected. For these aims, a sample size of 3000 people was deemed as sufficient.
The EUROSAF study has the main objective of evaluating in a population of hospitalized older subjects with AF the clinical benefit/risk ratio of the oral anticoagulant treatments in terms of mortality, major thromboembolic events and bleeding side-effects, giving important information regarding the appropriate prescription of anticoagulant therapy in this population.
KeywordsAtrial Fibrillation Muldimensional Prognostic Index Frailty Elderly Anticoagulants
EUROSAF Study Investigators group also includes: Nicolò Marchionni, Florence, Italy; Mario Durando, Padova, Italy; Nicola Ferrara, Napoli, Italy; Mario Bò, Torino, Italy; Mario Barbagallo, Palermo, Italy; Giovanni Ruotolo, Catanzaro, Italy; Hans Jurgen Heppner, Schwelm, Germany; Philipp Bahrmann, Wiesbaden, Germany; Regina Roller-Wirnsberger, Vienna, Austria; Gil Gregorio Pedro, Madrid, Spain; Alfonso Cruz-Jentoft, Madrid, Spain; Pedro Marques da Silva, Lisboa, Portugal; Heidi Gruner, Lisboa, Portugal; Nicolas Berg, Liege, Belgium; Eva Topinkova, Prague, Czech Republic; Hana Matejovska-Kubesova, Brno, Czech Republic; Tuomo Nieminen, Helsinki and Lappeenranta, Finland; Laura Pikkarainen,Helsinki, Finland; Juhani Rossinen, Helsinki, Finland Marc Paccalin, Poitiers, France; Anna Kearney-Schwartz, Nancy, France; Krzyszof Rewiuk, Cracow, Poland; Francesco Mattace-Raso, Rotterdam, The Netherlands; Peter Olexa, Košice, Slovakia.
This is a study of the Comprehensive Geriatric Assessment (CGA)-Special Interest Group of the European Union Geriatric Medicine Society. Funding for this study was provided by an unrestricted contribution by Bayer Pharma AG.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest
The study was approved by the Regione Liguria Ethics Committee, Genova, Italy. Registry Number 162REG2016, dated 08/06/2016, Section 2.
Informed consent will be obtained from all individual participants included in the study.
- 1.Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH et al (2013) Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61(18):1935–1944CrossRefPubMedGoogle Scholar
- 12.Pilotto A, Ferrucci L, Franceschi M, D’Ambrosio LP, Scarcelli C, Cascavilla L et al (2008) Development and validation of a multidimensional prognostic index for one-year mortality from comprehensive geriatric assessment in hospitalized older patients. Rejuvenation Res 11(1):151–161CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Pilotto A, Gallina P, Fontana A, Sancarlo D, Bazzano S, Copetti M et al (2013) Development and validation of a multidimensional prognostic index for mortality based on a standardized multidimensional assessment schedule (MPI-SVaMA) in community-dwelling older subjects. J Am Med Dir Assoc 14(4):287–292CrossRefPubMedGoogle Scholar
- 17.Gallucci M, Battistella G, Bergamelli C, Spagnolo P, Mazzuco S, Carlini A et al (2014) Multidimensional prognostic index in a cognitive impairment outpatient setting: mortality and hospitalizations. The Treviso Dementia (TREDEM) study. J Alzheimer’s Dis 42(4):1461–1468Google Scholar
- 19.Pilotto A, Sancarlo D, Daragjati J, Panza F (2015). Perspective: the challenge of clinical decision-making for drug treatment in older people. The role of multidimensional assessment and prognosis. Front Med 1:61. https://doi.org/10.3389/fmed.2014.00061
- 20.Pilotto A, Sancarlo D, Polidori MC, Cruz-Jentoft AJ, Mattace-Raso F, Paccalin M et al (2015) The MPI_AGE European Project: using Multidimensional Prognostic Indices (MPI) to improve cost-effectiveness of interventions in multimorbid frail older persons. Background, aim and design. Eur Geriatr Med 6(2):184–188CrossRefGoogle Scholar
- 21.Angleman SB, Santoni G, Pilotto A, Fratiglioni L, Welmer A-K (2015) Multidimensional prognostic index in association with future mortality and number of hospital days in a population-based sample of older adults: results of the EU Funded MPI_AGE Project. PloS one 10(7):e0133789CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Kowal P, Dowd Edward, J (2001) Definition of an older person. Proposed working definition of an older person in Africa for the MDS ProjectGoogle Scholar